{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/background-information/complications/","result":{"pageContext":{"chapter":{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 55fcd835-8d58-4415-a9e9-0a8add8d6d9d --><h2>What are the complications?</h2><!-- end field 55fcd835-8d58-4415-a9e9-0a8add8d6d9d -->","summary":"","htmlStringContent":"<!-- begin item 45d91bda-d74a-4586-baf3-11521733e060 --><!-- begin field f09e691f-0e66-42b7-8bef-2346d7d27426 --><p><strong>Complications of untreated or undertreated hyperthyroidism include:</strong></p><ul><li>Graves orbitopathy<ul><li>This is an autoimmune disorder, and in about 90% of cases it occurs in people with a current or past history of Graves' disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>]. About 25% of people with Graves' disease have Graves' orbitopathy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>Sight-threatening complications include dysthyroid optic neuropathy, severe corneal exposure and ulceration, or corneal breakdown leading to frank perforation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>].</li><li>It can affect a person's quality of life and psychosocial wellbeing due to possible distressing changes in facial appearance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li><li>Thyrotoxic crisis (thyroid storm)<ul><li>This is a rare and potentially life-threatening complication, which may occur after a trigger such as acute infection, trauma, pregnancy, surgery including thyroidectomy, or stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>It may occur in people with previously undiagnosed hyperthyroidism or those who have abruptly stopped antithyroid medication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>Clinical features reflect systemic decompensation and include fever, tachycardia, agitation, hyperthermia, hypertension, atrial fibrillation, heart failure, jaundice, delirium, and coma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The mortality rate is estimated at about 10% due to hyperthermia, cardiac arrhythmias, multi-organ failure, and sepsis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].</li></ul></li><li>Compression symptoms<ul><li>A large goitre may cause dysphagia or breathlessness due to oesophageal or tracheal compression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li></ul></li><li>Musculoskeletal<ul><li>Thyrotoxic periodic paralysis —  this is a rare complication characterized by muscle paralysis and hypokalaemia, which is more prevalent in Asian people with hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Franklyn and Boelaert, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li></ul></li><li>Cardiovascular<ul><li>Atrial fibrillation <ul><li>A review article notes that people with hyperthyroidism over 60 years of age have a three-fold increased risk of developing atrial fibrillation than euthyroid controls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>A primary care population-based cohort study (n = 586,460) found the risk for developing atrial fibrillation increased with decreasing serum TSH levels, compared with euthyroid controls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Selmer et al, 2012</a>]. The risk is also increased in older people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>A meta-analysis of individual-level data from five prospective cohort studies (n = 7,901 euthyroid cases and 810 cases with subclinical hyperthyroidism) analysed the risk of incident atrial fibrillation. During a mean follow-up of 8.8 years, the overall hazard ratio for incident atrial fibrillation was higher in people with subclinical hyperthyroidism than in those who were euthyroid, and the attributable risk for atrial fibrillation was 41.5% in people with subclinical hyperthyroidism. After age- and sex-adjusted analysis, incident atrial fibrillation was found to be more common in people with more severe subclinical hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Collet et al, 2012</a>].</li></ul></li><li>Heart failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Selmer et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].<ul><li>Atrial fibrillation is an independent predictor of the development of heart failure in people with hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>Premature atrial and ventricular beats and heart failure with preserved ejection fraction may be associated with severe subclinical hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>]. The American Thyroid Association (ATA) guidelines on hyperthyroidism note that the risk of atrial fibrillation is increased in people with subclinical hyperthyroidism who are older and have lower TSH levels [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>]. </li></ul></li></ul></li><li>Reduced bone mineral density and osteoporosis<ul><li>Overt hyperthyroidism is associated with an increased risk of osteoporosis and fracture [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Cooper and Biondi, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].</li><li>In a prospective cohort study with case-cohort sampling of 686 women aged 65 years and older with subclinical hyperthyroidism, there was a four-fold increased risk for vertebral fracture and a three-fold increased risk for hip fracture, compared with women with normal thyroid function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bauer, 2001</a>].</li></ul></li><li>Increased mortality<ul><li>There is an increased risk of death from all causes in people with hyperthyroidism and subclinical hyperthyroidism, including due to coronary heart disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].</li><li>A meta-analysis of individual-level data from 10 prospective cohort studies (n = 52,674) found that subclinical hyperthyroidism was associated with a 24% increased risk of all-cause mortality and 29% increased risk of coronary heart disease mortality. The cardiovascular mortality risk was greater in people with more severe subclinical hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Collet et al, 2012</a>].</li></ul></li><li>Mood disorders<ul><li>Psychosis (rare) has been noted to complicate some cases of severe hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li><li>Pregnancy<ul><li>There is an increased risk of miscarriage, pregnancy-induced hypertension, maternal heart failure, preterm delivery, intrauterine growth restriction, low birthweight, and fetal death, if maternal hyperthyroidism is inadequately controlled during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li><li>Fetal complications of maternal hyperthyroidism include intrauterine growth restriction, fetal goitre, fetal hydrops and heart failure, fetal or neonatal thyrotoxicosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].<ul><li>Fetal or neonatal thyrotoxicosis may occur as a result of thyroid-stimulating hormone receptor antibodies (TRAbs) crossing the placenta in women with Graves' disease, and stimulating the fetal thyroid [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].</li><li>The incidence of fetal and neonatal hyperthyroidism is between 1–5% in all women with active or a past history of Graves’ hyperthyroidism, and it is associated with an increased risk of fetal or neonatal morbidity and mortality if it is unrecognized and untreated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li></ul></li></ul></li></ul><!-- end field f09e691f-0e66-42b7-8bef-2346d7d27426 --><!-- end item 45d91bda-d74a-4586-baf3-11521733e060 -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}